Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply
- PMID: 27892985
- DOI: 10.1001/jamaoncol.2016.3947
Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply
Comment on
-
Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question.JAMA Oncol. 2017 Mar 1;3(3):416. doi: 10.1001/jamaoncol.2016.3941. JAMA Oncol. 2017. PMID: 27892994 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
